Related Experiment Video

Updated: Jun 22, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The role of antiangiogenesis therapy: bevacizumab and beyond

Hernán Cortés-Funes1

  • 1Hospital Universitario 12 de Octubre, ES-28041 Madrid, Spain. hcortes.hdoc@salud.madrid.org

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|June 18, 2009
PubMed

Insights

Angiogenesis, driven by vascular endothelial growth factor (VEGF), fuels tumor growth. Anti-VEGF therapies, like bevacizumab, show promise in treating advanced cancers by inhibiting tumor blood vessel formation.

Area of Science:

  • Oncology
  • Cancer Biology
  • Vascular Biology

Background:

  • Angiogenesis is crucial for tumor growth and metastasis.
  • Vascular Endothelial Growth Factor (VEGF) is a key mediator of angiogenesis.
  • Overexpression of VEGF correlates with poor cancer prognosis.

Purpose of the Study:

  • To review the role of angiogenesis in cancer.
  • To discuss the development and clinical data of anti-VEGF agents for advanced solid tumors.
  • To focus on the efficacy and safety of bevacizumab.

Main Methods:

  • Review of clinical trial data for anti-VEGF agents.
  • Analysis of bevacizumab's efficacy and safety profile.
  • Discussion of therapeutic strategies targeting VEGF.

Main Results:

  • Anti-VEGF agents are under development for advanced solid tumors (breast, colorectal, lung, renal).
  • Bevacizumab is the most advanced anti-VEGF agent in development for these tumor types.
  • Clinical data on the efficacy and safety of bevacizumab in trials are presented.

Conclusions:

  • Inhibition of VEGF is a promising therapeutic strategy in oncology.
  • Bevacizumab demonstrates potential for treating various advanced solid tumors.
  • Further investigation into bevacizumab's role in cancer therapy is warranted.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...